CoChat

Randomized double blind placebo-controlled trial of Saccharomyces cerevisiae CNCM I-3856 in irritable bowel syndrome: improvement in abdominal pain and bloating in those with predominant constipation

Open access
Spiller, Robin, Pélerin, Fanny, Cayzeele Decherf, Amélie, Maudet, Corinne, Housez, Béatrice, Cazaubiel, Murielle, Jüsten, Peter · 2016 · United European Gastroenterology Journal

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder characterized by recurrent abdominal pain and/or discomfort. Probiotics have been reported to benefit IBS symptoms but the level of benefit remains quite unclear. OBJECTIVE: This study was designed to assess the benefit of Saccharomyces cerevisiae I-3856 on IBS symptoms. METHODS: A randomized, double blind, placebo-controlled trial has been performed in 379 subjects with diagnosed IBS. Subjects were randomly supplemented with the probiotics (1000 mg) or placebo for 12 weeks. Questionnaires (gastrointestinal symptoms, stools, wellbeing, and quality of life) were completed. Primary endpoint was percentage of responders defined as having a 50% decrease in the weekly average "intestinal pain/discomfort score" for at least 4 out of the last 8 weeks of the study. RESULTS: There was no overall benefit of S. cerevisiae I-3856 on IBS symptoms and wellbeing in the study population. Moreover, S. cerevisiae I-3856 was not statistically significant predictor of the responder status of the subjects (p > 0.05). Planned subgroup analyses showed significant effect in the IBS-C subjects: improvement of gastrointestinal symptoms was significantly higher in active group, compared to placebo, on abdominal pain/discomfort and bloating throughout the study and at the end of the supplementation. CONCLUSIONS: In this study, S. cerevisiae I-3856 at the dose of 1000 mg per day does not improve intestinal pain and discomfort in general IBS patients. However, it seems to have an effect in the subgroup with constipation which needs further studies to confirm (NCT01613456 in ClinicalTrials.gov registry).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/2050640615602571

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Study design.
Figure 1. Study design.CC BY-NC · PubMed Central
Figure 2. Flow chart of subjects throughout the study.
Figure 2. Flow chart of subjects throughout the study.CC BY-NC · PubMed Central
Figure 3. Evolution of abdominal pain/discomfort (a), bloating (b) and composite score of IBS symptoms (c) in IBS-C subjects, during the 12-week consumption of active product (S. cerevisiae I-3856; crosses and discontinued line) and placebo product (circle and black line). Each IBS symptom was rated from 0 (null) to 7 (severe); composite score corresponds to the sum of the abdominal pain/discomfort score, bloating score, flatulence/borborygmi score, and difficulty with defecation score. Values are estimated means, with standard error represented by vertical bars. Statistically significant differences between groups are symbolized by *(p < 0.05).
Figure 3. Evolution of abdominal pain/discomfort (a), bloating (b) and composite score of IBS symptoms (c) in IBS-C subjects, during the 12-week consumption of active product (S. cerevisiae I-3856; crosses and discontinued line) and placebo product (circle and black line). Each IBS symptom was rated from 0 (null) to 7 (severe); composite score corresponds to the sum of the abdominal pain/discomfort score, bloating score, flatulence/borborygmi score, and difficulty with defecation score. Values are estimated means, with standard error represented by vertical bars. Statistically significant differences between groups are symbolized by *(p < 0.05).CC BY-NC · PubMed Central
Figure 4. AUC of abdominal pain/discomfort (a), bloating (b) and composite score of IBS symptoms (c) in IBS-C subjects over the 12 weeks of active product (S. cerevisiae I-3856; black bar) and placebo product (white bar) consumption. The AUC of the composite score corresponds to the sum of the AUC of the four IBS symptoms: abdominal pain/discomfort, bloating, flatulence/borborygmi, and difficulty with defecation Values are estimated means, with standard error represented by vertical bars. Statistically significant differences between groups are symbolized by *(p < 0.05) and **(p < 0.01).
Figure 4. AUC of abdominal pain/discomfort (a), bloating (b) and composite score of IBS symptoms (c) in IBS-C subjects over the 12 weeks of active product (S. cerevisiae I-3856; black bar) and placebo product (white bar) consumption. The AUC of the composite score corresponds to the sum of the AUC of the four IBS symptoms: abdominal pain/discomfort, bloating, flatulence/borborygmi, and difficulty with defecation Values are estimated means, with standard error represented by vertical bars. Statistically significant differences between groups are symbolized by *(p < 0.05) and **(p < 0.01).CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 28 references

Research works printed but not linked: 1

  1. Canavan C, 2014, Clin Epidemiol, 6, 71

Cited by

See all 87

Metadata

Authors
Spiller, R., Pélerin, F., Cayzeele Decherf, A., Maudet, C., Housez, B., Cazaubiel, M., & Jüsten, P.
Affiliations
  • Nottingham Digestive Diseases Biomedical Research Unit, Nottingham Digestive Diseases Centre, Nottingham, United Kingdom
  • Lesaffre (France) (FR)
  • Lesaffre Human Care, Lesaffre Group, Marcq en Baroeul, France
  • Biofortis–Mérieux NutriSciences, Saint-Herblain, France
Venue
United European Gastroenterology Journal
Publisher
Wiley
Published
2015-08-21
Volume
4
Issue
3
Pages
353-362
ISSN
  • 2050-6406 (ISSN-L)
  • 2050-6414
OpenAlex
W1821958984
Cited by
87
References
28
Citations by year
2026: 4 · 2025: 5 · 2024: 14 · 2023: 12 · 2022: 7 · 2021: 9 · 2020: 12 · 2019: 8 · 2018: 10 · 2017: 2 · 2016: 4
FWCI
5.56
Type
journal article
Language
en
Open access
Licence
  • cc-by-nc
  • journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations
  • United European Gastroenterology Journal (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
National Institute for Health and Care Research (NF-SI-0509-10005)
Topics
  • Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
  • Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
Keywords
irritable bowel syndrome, probiotics, irritable bowel syndrome with constipation, abdominal pain, bloating, constipation, functional gastrointestinal disorders, quality of life, probiotic supplementation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Randomized double blind placebo-controlled trial of Saccharomyces cerevisiae CNCM I-3856 in irritable bowel syndrome: improvement in abdominal pain and bloating in those with predominant constipation. https://app.cochat.ai/papers/10.1177/2050640615602571
The paper
Spiller, R., Pélerin, F., Cayzeele Decherf, A., Maudet, C., Housez, B., Cazaubiel, M., & Jüsten, P. (2016). Randomized double blind placebo-controlled trial of Saccharomyces cerevisiae CNCM I-3856 in irritable bowel syndrome: improvement in abdominal pain and bloating in those with predominant constipation. United European Gastroenterology Journal. https://doi.org/10.1177/2050640615602571

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.